Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma

被引：0
|
作者：
Rosenberg, J. E.
Weinberg, V. K.
Claros, C.
Ryan, C.
Lin, A. M.
Fong, L.
Brocks, D.
Small, E. J.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Alberta, Edmonton, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5109
引用
收藏
页数：1
相关论文
共 50 条
  • [21] UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Kay, A.
    Motzer, R. J.
    Figlin, R. A.
    Escudier, B.
    Oudard, S.
    Porta, C.
    Hutson, T. E.
    Bracarda, S.
    Hollaender, N.
    Urbanowitz, G.
    Ravaud, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
  • [22] Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
    Juengel, Eva
    Kim, Dana
    Makarevic, Jasmina
    Reiter, Michael
    Tsaur, Igor
    Bartsch, Georg
    Haferkamp, Axel
    Blaheta, Roman A.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2015, 19 (02) : 430 - 441
  • [23] Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.
    Milowsky, M. I.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Trout, A.
    Flaherty, A.
    Gerst, S.
    Al-Ahmadie, H.
    Ostrovnaya, I.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways
    Larkin, James M. G.
    Clarke, Rosemary E. J.
    Pickering, Lisa M.
    MEDICAL ONCOLOGY, 2009, 26 : 40 - 45
  • [25] Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways
    James M. G. Larkin
    Rosemary E. J. Clarke
    Lisa M. Pickering
    Medical Oncology, 2009, 26 : 40 - 45
  • [26] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Jennifer A. Chan
    Robert J. Mayer
    Nadine Jackson
    Paige Malinowski
    Eileen Regan
    Matthew H. Kulke
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1241 - 1246
  • [27] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1241 - 1246
  • [28] Phase I trial with carboplatin and RAD001 in metastatic breast cancer
    Eucker, J.
    Schwarzlose-Schwarck, S.
    Martus, P.
    Regierer, A. C.
    Schulz, C. O.
    Liu, H.
    Scholz, C. W.
    Schefe, J. H.
    Possinger, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Everolimus (RAD001) activity in renal and hepatocellular carcinoma cells resistant to sunitinib and sorafenib
    Serova, Maria
    Riveiro, Maria Eugenia
    Dokmak, Safi
    Faivre, Sandrine
    Raymond, Eric
    CANCER RESEARCH, 2011, 71
  • [30] A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC)
    Cen, P.
    Daleiden, A.
    Doshi, G.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345